Phase I-II study on weekly administration of pirarubicin in patients with metastatic breast cancer.

Phase II study of pirarubicin in metastatic breast cancer.

Phase II study of pirarubicin (THP-adriamycin) in metastatic breast cancer patients.

Phase III studies of toremifene in metastatic breast cancer.

Pirarubicin in advanced breast cancer: a French cooperative phase II study.

Phase II study of edatrexate in chemotherapy-naive patients with metastatic breast cancer.

Phase II clinical study of toremifene in patients with metastatic breast cancer. Preliminary communication.

Cisplatin improves antitumor activity of weekly nab-paclitaxel in patients with metastatic breast cancer.

Phase I study of weekly nab-paclitaxel combined with S-1 in patients with human epidermal growth factor receptor type 2-negative metastatic breast cancer.

Trastuzumab Administration in Patients with Metastatic Breast Cancer - Experience of a Large University Breast Center.

II Study of Weekly Oraxol for the Second-Line Treatment of Patients With Metastatic or Recurrent Gastric Cancer.

Weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer: overall survival and updated progression-free survival results from a phase II study.

"Classical" CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer. An EORTC Breast Cancer Co-operative Group Phase III Trial (10808).

Elliptinium acetate in metastatic breast cancer--a phase II study.

A phase II clinical trial of weekly paclitaxel and carboplatin in combination with panitumumab in metastatic triple negative breast cancer.

Phase I Study of Panobinostat (LBH589) and Letrozole in Postmenopausal Metastatic Breast Cancer Patients.

Phase I study with combination therapy of pirarubicin, etoposide, and vincristine in small-cell lung cancer.

Carboplatin activity in untreated metastatic breast cancer patients--results of a phase II study.

Phase II study of weekly 4'-epidoxorubicin in patients with metastatic squamous cell cancer of the cervix: an EORTC Gynaecological Cancer Cooperative Group Study.

Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA.

Phase II study of lonidamine in patients with metastatic breast cancer. An Eastern Cooperative Oncology Group study.

Metastatic breast cancer in patients with schizophrenia.

A Randomized, Open-Label, Multicenter, Phase III Study of Epoetin Alfa Versus Best Standard of Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy.

A phase III trial of exemestane plus bevacizumab maintenance therapy in patients with metastatic breast cancer after first-line taxane and bevacizumab: a GINECO group study.

Clinical study of pirarubicin for breast cancer in Japan. Clinical Study Group of THP for Breast Cancer in Japan.

Suggest Documents

Phase II study of pirarubicin in metastatic breast cancer.

Phase II study of pirarubicin (THP-adriamycin) in metastatic breast cancer patients.

Phase III studies of toremifene in metastatic breast cancer.

Pirarubicin in advanced breast cancer: a French cooperative phase II study.

Phase II study of edatrexate in chemotherapy-naive patients with metastatic breast cancer.

Phase II clinical study of toremifene in patients with metastatic breast cancer. Preliminary communication.

Cisplatin improves antitumor activity of weekly nab-paclitaxel in patients with metastatic breast cancer.

Phase I study of weekly nab-paclitaxel combined with S-1 in patients with human epidermal growth factor receptor type 2-negative metastatic breast cancer.

Trastuzumab Administration in Patients with Metastatic Breast Cancer - Experience of a Large University Breast Center.

II Study of Weekly Oraxol for the Second-Line Treatment of Patients With Metastatic or Recurrent Gastric Cancer.

Weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer: overall survival and updated progression-free survival results from a phase II study.

"Classical" CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer. An EORTC Breast Cancer Co-operative Group Phase III Trial (10808).

Elliptinium acetate in metastatic breast cancer--a phase II study.

A phase II clinical trial of weekly paclitaxel and carboplatin in combination with panitumumab in metastatic triple negative breast cancer.

Phase I Study of Panobinostat (LBH589) and Letrozole in Postmenopausal Metastatic Breast Cancer Patients.

Phase I study with combination therapy of pirarubicin, etoposide, and vincristine in small-cell lung cancer.

Carboplatin activity in untreated metastatic breast cancer patients--results of a phase II study.

Phase II study of weekly 4'-epidoxorubicin in patients with metastatic squamous cell cancer of the cervix: an EORTC Gynaecological Cancer Cooperative Group Study.

Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA.

Phase II study of lonidamine in patients with metastatic breast cancer. An Eastern Cooperative Oncology Group study.

Metastatic breast cancer in patients with schizophrenia.

A Randomized, Open-Label, Multicenter, Phase III Study of Epoetin Alfa Versus Best Standard of Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy.

A phase III trial of exemestane plus bevacizumab maintenance therapy in patients with metastatic breast cancer after first-line taxane and bevacizumab: a GINECO group study.

Clinical study of pirarubicin for breast cancer in Japan. Clinical Study Group of THP for Breast Cancer in Japan.

Phase I-II study on weekly administration of pirarubicin in patients with metastatic breast cancer.

Recommend Documents

Follow Us